ISSN: 2161-0495
Arvind Kumar, Jai Prakash*, Kirti Berwal, Gaurav Arya, Varun Narwal, Ekal Arora, Anoop Kumar, Nisha Yadav, Dhruva Chaudhry, Aman Dhankar, Sonalika Arora, Anand Kumar Yadav, Jagjeet Singh, Aman Ahuja, Pawan Kumar Singh
Purpose: Aluminium phosphide poisoning is common among agriculture dominant economies especially southeast Asia. Mitochondrial toxicity caused by AlP leads to hemodynamic collapse without any antidote. Mortality is high despite optimum supportive care. In anecdotal studies Extra-Corporeal Membrane Oxygenation (ECMO) has been shown to reduce mortality.
Methods: This was a retrospective single centre study of aluminium phosphide cases managed from 2019 to 2023. Data of all cases who underwent treatment with ECMO was retrieved and analyzed.
Results: Of 182 cases admitted with diagnosis of AlP poisoning 78 underwent VA (Veno-Arterial) ECMO (mean age 34.4years). 60 (76.9%) had multi-organ dysfunction at the time of presentation. 74 (94.9%) of the subjects had ECG changes. ECMO was initiated in emergency room in 68 (87.2%) whereas in 8 (10.3%) ECMO was initiate during CPR. Most subjects required concurrent renal replacement therapy initiation (53, 67.9%). Mean time to ECMO initiation was 1.48 ± 1.2 hours from arrival to ER. Mean duration of ECMO was 50.1 ± 23.9 hours and mean ICU length of stay was 7.17 ± 5.6 days. Out of 78 cases, 53 survived and 25 expired despite ECMO support. During the hospital stay, 15 (19.2%) developed one or the other ECMO related complications lactate levels at the time of arrival were significantly higher among the patients who died (p=0.026).
Conclusion: VA-ECMO was found to be associated with significant survival benefit in high risk cases of AlP poisoning. Close monitoring of the blood gas parameters and cardiac function variables is vital for identifying the potentially salvageable cases.
Published Date: 2026-06-19; Received Date: 2025-01-31